On January 8, 2016, Puma Biotechnology, Inc. announced that shareholders representing over 80% of the Company's shares outstanding have rejected the proposals initiated by Fredric Eshelman by revoking consent on the Company's consent revocation card or affirmatively withholding consent on Eshelman's card.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.28 USD | +0.61% |
|
+12.33% | -24.25% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.25% | 158M | |
+16.59% | 44.44B | |
-9.89% | 37.99B | |
+35.82% | 37.75B | |
+27.12% | 30.78B | |
-8.64% | 27.38B | |
+11.81% | 26.17B | |
+45.08% | 14.15B | |
+32.85% | 12.59B | |
-7.19% | 11.28B |
- Stock Market
- Equities
- PBYI Stock
- News Puma Biotechnology, Inc.
- Puma Biotechnology Shareholders Rejects Fredric N. Eshelman’s Consent Solicitation